Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: Clin Breast Cancer. 2019 Sep 30;20(3):e261–e280. doi: 10.1016/j.clbc.2019.09.005

Table 4:

Sensitivity analysis: medication regimen effects in multivariable models limited to stage I-III breast cancer patients with adjustment for adjuvant chemotherapy use, compared to primary analysis results

Initiation aDiscontinuation bAdherence
Full Cohort
n=21,244		 Bipolar and
Psychotic Disorder
n=1,225		 Full Cohort
n=17,020		 Bipolar and
Psychotic Disorder
n=928		 Full Cohort
n=17,020		 Bipolar and
Psychotic Disorder
n=928
Parameter Sensitivity Analysis
Hazard Ratio
(Primary Analysis)		 Sensitivity Analysis
Hazard Ratio
(Primary Analysis)		 Sensitivity Analysis
Hazard Ratio
(Primary Analysis)		 Sensitivity Analysis
Hazard Ratio
(Primary Analysis)		 Sensitivity Analysis
Estimate
(Primary Analysis)		 Sensitivity Analysis
Estimate
(Primary Analysis)
MRCI-A Route Complexity 2-4 *0.96 (*0.96) 0.98 (1.00) 1.07 (1.07) 0.93 (0.94) 0.002 (0.001) 0.008 (0.007)
(ref= 0-1) 5+ 0.99 (1.00) 0.98 (0.97) *1.12 (*1.12) 1.03 (1.00) **0.015 (**0.014) 0.019 (0.016)
Combined Medication & Visit Score 1-3 Meds **1.29 (**1.34) 0.78 (0.88) *0.72 (*0.71) 0.96 (1.01) *0.028 (*0.024) −0.031 (−0.035)
(ref= No Meds) 4+ Meds or 2+ Visits **1.33 (**1.36) 0.75 (0.87) **0.56 (**0.56) 0.76 (0.78) **0.052 (**0.049) 0.040 (0.032)
4+ Meds & 2+ Visits **1.43 (**1.47) 0.92 (1.07) **0.49 (**0.48) 0.60 (0.64) **0.062 (**0.060) 0.065 (0.063)
Out-of-Pocket Medication Costs $1 < $50 1.02 (0.98) 1.14 (1.04) 1.16 (1.17) 1.23 (1.18) **−0.022 (**−0.021) −0.021 (−0.021)
(ref= $0 < $1) $50 < $500 1.00 (0.96) 1.05 (0.96) *1.30 (*1.31) *1.57 (1.43) **−0.043 (**−0.042) **−0.069 (**−0.069)
$500+ *0.91 (*0.86) *0.78 (*0.73) *1.23 (*1.25) 1.47 (1.36) **−0.039 (**−0.037) **−0.063 (**−0.065)
Adjuvant Chemotherapy Prior to Endocrine Therapy **0.48 (n/a) **0.52 (n/a) **0.83 (n/a) 0.80 (n/a) −0.003 (n/a) −0.018 (n/a)

P value *<0.05, **<0.001. Models adjusted for same variables in primary analysis: stage, age, race, ethnicity, NCI comorbidity score, function-related indicators, rurality, mental illness, year of diagnosis.

a,b

Follow-up began the day of endocrine therapy initiation, concluding at censoring or a maximum five years of endocrine therapy use.

a

Discontinuation analysis censored after five years continuous use.

b

Adherence measured with the proportion of days covered (PDC), for patients with one or more years of observation with over half of this time outside hospitals and skilled nursing facilities. Estimate of 0.01 corresponds to 1%.